FDA user fee plan
This article was originally published in The Tan Sheet
Agency is authorized to collect $740 mil. in fees over five years, with $456 mil. of that to be used to maintain improvements, such as faster review times, wrought by the first Prescription Drug User Fee Act and to sustain 659 staff-years of program each year that made those improvements possible, according to the FDA PDUFA II five-year plan, whose availability FDA announced July 10. The remaining $284 mil. will be invested to enable FDA to meet the new PDUFA II goals, the agency says. CDER will receive 56% of the total. Of the overall monies, 58% will go for pay and benefits for additional agency staff (983 more staff-years, i.e., 325 more FTEs in 2002 than in the drug evaluation process in 1992) and 13% for information technology...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC